Back to Search
Start Over
Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?
- Source :
-
Headache [Headache] 2019 Oct; Vol. 59 (9), pp. 1659-1661. Date of Electronic Publication: 2019 Sep 11. - Publication Year :
- 2019
-
Abstract
- Trigeminal-targeted treatments (TTTs), the most specific and selective therapeutic migraine approach to date, are effective in approximately 60% of patients regardless of treatment type or mechanism, at least if used alone. Sixty percent is also the proportion of migraineurs who develop migraine-like episodes following experimental intravenous administration of trigeminal neuropeptides and roughly 60% is the percentage of patients with a unilateral migraine tracing the area of cutaneous distribution of the trigeminal ophthalmic branch. Hence, mechanisms other than the trigeminovascular activation are probably involved in the 40% of migraineurs who do not respond to TTTs. A closer cooperation between clinical and basic neuroscientists is needed to explore migraine models because only a careful appraisal of migraine endophenotypes may help to unravel their underlying multifaceted pathophysiological machinery.<br /> (© 2019 American Headache Society.)
- Subjects :
- Drug Delivery Systems
Humans
Migraine Disorders etiology
Migraine Disorders physiopathology
Neuropeptides
Trigeminal Ganglion physiopathology
Trigeminal Nerve chemistry
Trigeminal Nerve drug effects
Trigeminal Nerve physiopathology
Trigeminal Nerve Diseases complications
Trigeminal Nerve Diseases physiopathology
Tryptamines therapeutic use
Migraine Disorders therapy
Trigeminal Nerve Diseases therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1526-4610
- Volume :
- 59
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Headache
- Publication Type :
- Academic Journal
- Accession number :
- 31508812
- Full Text :
- https://doi.org/10.1111/head.13635